Rahway, New Jersey, USA, November 17, 2026
Merck & Co., Inc. has announced the discontinuation of its entire BELLWAVE clinical development programme evaluating nemtabrutinib (MK-1026), an investigational oral treatment for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and other blood cancers. The decision follows a review of the Phase 3 BELLWAVE-011 study by an external Data Monitoring Committee (eDMC), which concluded that the potential benefits of nemtabrutinib might not outweigh the risks in the study. Merck subsequently conducted its own comprehensive review of the available data and confirmed the decision to discontinue development. The announcement includes the termination of BELLWAVE-011 and the other ongoing Phase 3 studies, BELLWAVE-008 and BELLWAVE-010. The development update represents a setback for the company’s investigational oncology pipeline and highlights the importance of ongoing safety and benefit-risk assessments during late-stage clinical research.
Merck Discontinues Phase 3 BELLWAVE-011 Trial
The decision to stop the programme originated from the review of BELLWAVE-011 (NCT06136559), a Phase 3 clinical study evaluating nemtabrutinib in patients with blood cancer. An independent external Data Monitoring Committee assessed the study results and determined that the potential benefits might not outweigh the associated risks. Following this recommendation, Merck reviewed the totality of the available clinical data and reached the same conclusion. The company therefore decided to discontinue nemtabrutinib development across the entire BELLWAVE programme rather than limiting the decision to the individual study. Merck has not publicly disclosed the specific safety concerns or detailed numerical efficacy findings that led to the decision. The discontinuation should therefore be understood as a benefit-risk decision, not as evidence that a particular adverse event or clinical outcome has been established publicly. Data analyses from the discontinued studies are continuing, and the company has stated that findings will be shared with the scientific community. The decision also reflects the role of independent monitoring committees in reviewing accumulating clinical evidence and identifying situations where continued investigation may no longer be appropriate.
Nemtabrutinib Targeted BTK Signalling in Blood Cancers
Nemtabrutinib, also known as MK-1026, is an investigational, orally administered, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. BTK is an important component of B-cell receptor signalling, a pathway involved in the growth, survival and activity of B cells. In certain blood cancers, abnormal signalling through this pathway can contribute to the development and persistence of malignant B cells. Nemtabrutinib was designed to inhibit BTK activity and suppress oncogenic B-cell receptor signalling. The candidate was being investigated for patients with chronic lymphocytic leukemia, small lymphocytic lymphoma and other hematologic malignancies. These conditions are associated with abnormal lymphocyte growth and can require long-term treatment strategies to control disease progression. The BELLWAVE programme formed part of Merck’s broader efforts to develop targeted therapies for patients with hematological cancers. Its clinical evaluation included multiple studies examining nemtabrutinib in different treatment settings. However, the decision to discontinue the programme means the investigational medicine will no longer advance through these planned clinical development pathways. Nemtabrutinib has not received regulatory approval and will not become an available treatment through this discontinued programme.
BELLWAVE-008 and BELLWAVE-010 Also Discontinued
Following its review, Merck confirmed that the decision extends beyond BELLWAVE-011 to include the other Phase 3 studies, BELLWAVE-008 (NCT05624554) and BELLWAVE-010 (NCT05947851). These studies were part of the broader evaluation of nemtabrutinib in patients with hematological malignancies. The company is notifying clinical investigators involved in the affected trials and has advised enrolled patients to consult their study teams and treating physicians regarding appropriate next steps and alternative treatment options. Patients should not independently change or discontinue any prescribed treatment without discussing their care with their healthcare professionals. Merck also expressed appreciation to the patients, caregivers and investigators who contributed to the clinical programme. The company continues to pursue other research approaches for hematological malignancies and intends to advance its broader oncology and hematology pipeline.
The discontinuation of the BELLWAVE programme marks an important development in the clinical evaluation of investigational BTK inhibitors. The full trial analyses will be important for understanding the benefit-risk findings and informing future research in CLL, SLL and other blood cancers. Merck has indicated that additional results will be communicated to the scientific community as the analyses progress. The decision underscores the importance of evaluating both treatment benefit and patient safety throughout clinical development, particularly in large Phase 3 programmes.
Source: Merck press release



